TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07676162: A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With mFOLFOX6 (-1) and Bevacizumab Versus mFOLFOX6 in Combination With Bevacizumab as First-line Treatment for Advanc

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07676162 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07676162 Rescue Dossier →